A leader in preclinical research
PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development.
We are known for our cutting-edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into the clinic.
With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, we enable clients to deliver much needed superior clinical candidates to patients.
Our capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.
Alzheimer’s Disease and Frontotemporal Dementia ASD and Neurodevelopment Disorders Pharmacokinetics/Exogenous Molecules Quantification of Phosphoproteins and Secondary Messengers Rodent Primary Neurons and Glia Culture
Bioanalysis & Microdialysis
Alzheimer’s Disease and Frontotemporal Dementia
ASD and Neurodevelopment Disorders
Quantification of Phosphoproteins and Secondary Messengers
Rodent Primary Neurons and Glia Culture
High-throughput phenotypic drug discovery
Using artificial intelligence, We have pioneered the translation of rodent behavioral and physiological responses into robust, high throughput, high content phenotyping. Our drug discovery platforms, SmartCube®, NeuroCube®, PhenoCube® and eCube™, have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials, including SEP-363856. SEP363856 is a novel, first-in-class drug treatment for schizophrenia being developed by Sunovion Pharmaceuticals.
PsychoGenics employs computer vision and AI to extract and analyze behavioral and physiological data from mice and offers an effective approach to the discovery and development of the next generation of breakthrough treatments for CNS disorders.
News & Events
May 10, 2023AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’
April 6, 2023PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery
February 28, 2023PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day
Careers at Psychogenics
At PsychoGenics we value teamwork, excellence, creativity and entrepreneurial drive. We are excited about our mission and endeavor each day to build a company that fosters that excitement. Our employees are our most important and valued asset and we are committed to the creation of a working environment that encourages each employee’s professional and personal development. We believe in rewarding the efforts of our employees through competitive compensation and a comprehensive benefits plan.